edg-5506
Small moleculeexperimental
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 12, 2020 (NCT04585464)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
O=c1ccc(-c2cnc(OCC(F)(F)F)nc2)nn1Cc1cncc(F)c1- Mol. weight
- 381.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314486 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06916897 | Phase 1 | Jan 8, 2025 | Edgewise Therapeutics, Inc. |
| NCT06100887 | Phase 2 | Dec 31, 2023 | Edgewise Therapeutics, Inc. |
| NCT06066580 | Phase 2 | Nov 2, 2023 | Edgewise Therapeutics, Inc., Medpace, Inc. |
| NCT05730842 | Phase 1 | Jan 12, 2023 | Edgewise Therapeutics, Inc. |
| NCT05540860 | Phase 2 | Oct 31, 2022 | Edgewise Therapeutics, Inc. |
| NCT05492734 | Phase 1 | Aug 12, 2022 | Edgewise Therapeutics, Inc. |
| NCT05291091 | Phase 2 | Jul 6, 2022 | Edgewise Therapeutics, Inc., Medpace, Inc., Sysnav |
| NCT05160415 | Phase 1 | Dec 31, 2021 | Edgewise Therapeutics, Inc., Medpace, Inc. |
| NCT04585464 | Phase 1 | Oct 12, 2020 | Edgewise Therapeutics, Inc., Worldwide Clinical Trials |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc. | For profit | 9 | 9 | 2 | 2020 |
| Medpace, Inc. | For profit | 3 | 0 | 2 | 2021 |
| Sysnav | For profit | 1 | 0 | 1 | 2022 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1